China Pharma Holdings, Inc. — Q1 2015 Form 10-Q
Business context and reporting period. Unaudited consolidated results for the three months ended March 31, 2015, compared with Q1 2014. The company manufactures and markets generic and branded pharmaceuticals and biochemical products, primarily in China. Results are presented in U.S. dollars; substantially all operations and revenue are in the PRC.
Financial performance
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $5.69 million | $7.11 million |
| Gross profit / margin | $1.06 million / 19% | $2.66 million / 37% |
| Operating loss | $7.67 million | $2.34 million |
| Net loss | $7.97 million | $2.39 million |
| Loss per share, basic and diluted | $0.18 | $0.05 |
| Operating cash flow | $(2,239) | $2.49 million |
| Investing cash flow | $(47,106) | $(3.75) million |
At March 31, 2015, cash was $5.27 million, current assets $48.11 million, and current liabilities $14.67 million (working capital approximately $33.44 million). Total assets were $125.16 million and total liabilities $26.40 million. Debt included $4.91 million in short-term notes due November 24, 2015, and a construction loan with $13.10 million outstanding; $1.64 million of the construction loan was current. Cash held in the PRC subsidiary was described as indefinitely reinvested and not expected to be available for parent-company or shareholder payments.
Material changes and drivers
- Revenue fell 20%. Anti-infection/respiratory sales declined to $4.1 million, primarily due to lower Cefaclor demand; CNS/cardiovascular and digestive product sales were also lower, partly following 2014 injectable-line production suspensions.
- Gross margin fell to 19% from 37%. Management cited outsourced product costs from the prior-year production suspensions, lower efficiency at new production lines, and a $0.20 million inventory obsolescence charge.
- Bad debt expense rose to $7.10 million from $3.31 million, mainly due to aging receivables. Net trade receivables were $18.81 million, while the doubtful-account allowance was $40.64 million. Receivables over 720 days represented 66% of the reported aging distribution.
- Selling expense increased to $0.99 million; R&D expense decreased to $0.16 million, mainly reflecting lower production-line upgrade costs. Interest expense rose to $0.31 million from $0.06 million.
- Cash and equivalents decreased by $26,934 during the quarter. Operating cash flow was approximately break-even, versus $2.49 million generated in Q1 2014.
Outlook, risks and other matters
- Management said operating cash was expected to cover working capital, scheduled debt repayment, and planned capital expenditures for the next 12 months, but warned that weaker-than-planned operations could require additional financing or spending reductions. It gave no quantified earnings or revenue guidance.
- The company reported receiving GMP certificates for four new injectable lines in November 2014 and tablet and capsule lines in January 2015. It planned further upgrades to certain older production lines by the end of 2015. CFDA review delays and stricter requirements were delaying pipeline products; approvals typically take two to five years.
- Management cited pharmaceutical pricing and healthcare cost-control pressure, market volatility, collection difficulties, and the risk that new production lines may remain inefficient. PRC foreign-exchange conversion and remittance approvals may restrict transfers of funds abroad.
- One customer represented 19.7% of Q1 2015 sales and 17.3% of period-end receivables. One supplier accounted for 29.5% of raw-material purchases.
- The filing reports no off-balance-sheet arrangements. It describes approximately $4.6 million of future formula-contract payments in MD&A, but approximately $5.19 million in a financial-statement note; payments depend on completion of contract phases.
- Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts to verify
- Reconcile the conflicting formula-contract commitment amounts: approximately $4.6 million in MD&A versus $5.19 million in the note.
- Review receivable aging, the substantial allowance, collection assumptions, and the effect of further customer delays or write-offs.
- Confirm the availability of subsidiary cash for debt service and parent-company needs, given PRC remittance controls and the indefinitely reinvested designation.
- Check the filing’s reported share-count date: it says 43,579,557 shares were outstanding as of May 5, 2014, although this is a 2015 quarterly filing.
- Reconcile the income-tax presentation: the statements show a $19,284 tax expense, while MD&A describes an income-tax benefit of approximately $0.02 million.